The molecular basis of psychotherapy: Focus on BDNF in talking therapies
Journal of Clinical and Basic Psychosomatics · 2024
DOI: 10.36922/jcbp.4461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Basic Psychosomatics, 2024. Verfasst von Zhi Xu und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Psychotherapy is effective in treating various types of mental disorders. However, the biological processes underlying its therapeutic efficacy in the relief of depression and anxiety remain unclear. An approach to investigating these therapeutic mechanisms derives from an understanding of disease pathogenesis, in which the dysfunction of brain-derived neurotrophic factor (BDNF) is strongly implicated. This study provides a review of various studies investigating the link between the efficacy of talking therapies in anxiety and depression and the measures of BDNF variability, the latter determined by plasma and serum BDNF concentrations, BDNF gene polymorphisms, and DNA methylation. Despite the few intriguing findings supporting the underlying hypothesis that reduced BDNF function results in poor response, many studies are limited by inadequate methodology and poor control of confounding factors. Thus, opportunities remain for further well-designed investigations, particularly utilizing the little-studied epigenetic factor of BDNF gene methylation.
Zitieren
APA
Xu, Z., Yao, Y., & Reynolds, G. P. (2024). The molecular basis of psychotherapy: Focus on BDNF in talking therapies. Journal of Clinical and Basic Psychosomatics. https://doi.org/10.36922/jcbp.4461
Vancouver
Xu Z, Yao Y, Reynolds GP. The molecular basis of psychotherapy: Focus on BDNF in talking therapies. Journal of Clinical and Basic Psychosomatics. 2024. doi:10.36922/jcbp.4461
BibTeX
@article{Xu2024,
author = {Xu, Zhi and Yao, Yihan and Reynolds, Gavin P.},
title = {The molecular basis of psychotherapy: Focus on BDNF in talking therapies},
journal = {Journal of Clinical and Basic Psychosomatics},
year = {2024},
doi = {10.36922/jcbp.4461}
}
EUVIMED